The inexpensive lab-on-a-chip technology has the potential to enhance diagnostic capabilities around the world, especially in developing countries. Due to inferior access to early diagnostics, the survival rate of breast cancer patients is only 40 percent in low-income nations — half the rate of such patients in developed nations. Other lethal diseases, such as malaria, tuberculosis and HIV, also have high incidence and bad patient outcomes in developing countries. Better access to cheap diagnostics could help turn this around, especially as most such equipment costs thousands of dollars.
“Enabling early detection of diseases is one of the greatest opportunities we have for developing effective treatments,” Esfandyarpour said. “Maybe $1 in the U.S. doesn’t count that much, but somewhere in the developing world, it’s a lot of money.”
A two-part system
A combination of microfluidics, electronics and inkjet printing technology, the lab-on-a-chip is a two-part system: A clear silicone microfluidic chamber for housing cells sits on top of a reusable electronic strip.A regular inkjet printer that can be used to print the electronic strip onto a flexible sheet of polyester using commercially available conductive nanoparticle ink.
“We designed it to eliminate the need for clean-room facilities
and trained personnel to fabricate such a device,” said Esfandyarpour,
an electrical engineer by training. One chip can be produced in about 20
minutes, he said.
Designed as a multifunctional platform, one of its applications is that it allows users to analyze different cell types without using fluorescent or magnetic labels that are typically required to track cells. Instead, the chip separates cells based on their intrinsic electrical properties: When an electric potential is applied across the inkjet-printed strip, cells loaded into the microfluidic chamber get pulled in different directions depending on their “polarizability” in a process called dielectrophoresis. This label-free method to analyze cells greatly improves precision and cuts lengthy labeling processes.
The tool is designed to handle small-volume samples for a variety of assays. The researchers showed the device can help capture single cells from a mix, isolate rare cells and count cells based on cell types. The cost of these multifunctional biochips is orders of magnitude lower than that of the individual technologies that perform each of those functions. A standalone flow cytometer machine, for example, which is used to sort and count cells, costs $100,000, without taking any operational costs into account.
Designed as a multifunctional platform, one of its applications is that it allows users to analyze different cell types without using fluorescent or magnetic labels that are typically required to track cells. Instead, the chip separates cells based on their intrinsic electrical properties: When an electric potential is applied across the inkjet-printed strip, cells loaded into the microfluidic chamber get pulled in different directions depending on their “polarizability” in a process called dielectrophoresis. This label-free method to analyze cells greatly improves precision and cuts lengthy labeling processes.
The tool is designed to handle small-volume samples for a variety of assays. The researchers showed the device can help capture single cells from a mix, isolate rare cells and count cells based on cell types. The cost of these multifunctional biochips is orders of magnitude lower than that of the individual technologies that perform each of those functions. A standalone flow cytometer machine, for example, which is used to sort and count cells, costs $100,000, without taking any operational costs into account.
Potential to democratize diagnostics
“The motivation was really how to export technology and how to decrease the cost of things,” Davis said.
The low cost of the chips could democratize diagnostics similar
to how low-cost sequencing created a revolution in health care and
personalized medicine, Davis said. Inexpensive sequencing technology
allows clinicians to sequence tumor DNA to identify specific mutations
and recommend personalized treatment plans. In the same way, the lab on a
chip has the potential to diagnose cancer early by detecting tumor
cells that circulate in the bloodstream. “The genome project has changed
the way an awful lot of medicine is done, and we want to continue that
with all sorts of other technology that are just really inexpensive and
accessible,” Davis said.
The technology has the potential to not only advance health care, but also to accelerate basic and applied research. It would allow scientists and clinicians to potentially analyze more cells in shorter time periods, manipulate stem cells to achieve efficient gene transfer and develop cost-effective ways to diagnose diseases, Esfandyarpour said. The team hopes the chip will create a transformation in how people use instruments in the lab. “I’m pretty sure it will open a window for researchers because it makes life much easier for them — just print it and use it,” he said.
The work is an example of Stanford Medicine’s focus on precision health, the goal of which is to anticipate and prevent disease in the healthy and precisely diagnose and treat disease in the ill.
Other Stanford co-authors of the study are graduate students Matthew DiDonato and Yuxin Yang; postdoctoral scholar Naside Gozde Durmus, PhD; and James Harris, PhD, professor of electrical engineering.
The research was supported by a grant from the National Institutes of Health (grant HG000205).
The departments of Biochemistry and of Genetics also supported the work.
The technology has the potential to not only advance health care, but also to accelerate basic and applied research. It would allow scientists and clinicians to potentially analyze more cells in shorter time periods, manipulate stem cells to achieve efficient gene transfer and develop cost-effective ways to diagnose diseases, Esfandyarpour said. The team hopes the chip will create a transformation in how people use instruments in the lab. “I’m pretty sure it will open a window for researchers because it makes life much easier for them — just print it and use it,” he said.
The work is an example of Stanford Medicine’s focus on precision health, the goal of which is to anticipate and prevent disease in the healthy and precisely diagnose and treat disease in the ill.
Other Stanford co-authors of the study are graduate students Matthew DiDonato and Yuxin Yang; postdoctoral scholar Naside Gozde Durmus, PhD; and James Harris, PhD, professor of electrical engineering.
The research was supported by a grant from the National Institutes of Health (grant HG000205).
The departments of Biochemistry and of Genetics also supported the work.